BI 3000202 Clinical Trials (2026): 7 Studies for Healthy & Hepatic Impairment
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
7 BI 3000202 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 3 indications (including Healthy & Hepatic Impairment) and 599 total planned enrollment. 2 BI 3000202 clinical trials are actively recruiting at 1 U.S. site across 1 state. Most recent activity: NCT07409181 (Jul 2029).
Where to Participate: All BI 3000202 Trial Sites in the U.S. (1 site across 1 state)
Every actively recruiting BI 3000202trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| TX | American Research Corporation at the Texas Liver Institute | San Antonio78215 | NCT07486102 | Map |
BI 3000202 clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | completed | Total |
|---|---|---|---|---|
| P1 | 1 | 1 | 4 | 6 |
| P2 | 1 | 1 |
Recruiting BI 3000202 clinical trials (2)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07409181 | SLEA Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE) | P2 | Systemic Lupus Erythematosus | 405 | Apr 2026 |
| NCT07486102 | A Study to Test How BI 3000202 is Taken up in the Blood of People With and Without Liver Problems | P1 | Healthy | 44 | May 2026 |
BI 3000202 clinical trials by indication
Healthy (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07486102 | — | P1 | recruiting | A Study to Test How BI 3000202 is Taken up in the Blood of People With and Without Liver Problems |
| NCT07273474 | — | P1 | completed | A Study in Healthy Men and Women to Test How BI 3000202 is Taken up and Processed by the Body |
| NCT07215260 | — | P1 | completed | A Study in Healthy People to Test Whether BI 3000202 Affects How 2 Other Medicines (Rosuvastatin and Digoxin) Are Taken up in the Body |
| NCT06327256 | — | P1 | completed | A Study in Healthy People to Test How Well Different Doses of BI 3000202 Are Tolerated and How They Affect the Way the Body Handles Midazolam |
| NCT05945888 | — | P1 | completed | A Study in Healthy Men to Test How Different Doses of BI 3000202 Are Tolerated and How Food Influences the Amount of BI 3000202 in the Blood |
Systemic Lupus Erythematosus (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07409181 | SLE | P2 | recruiting | A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE) |
Type 1 Interferonopathies (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06878365 | — | P1 | active not recruiting | A Study to Test How Well BI 3000202 is Tolerated by People With Type 1 Interferonopathies |
BI 3000202 pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| SLE | NCT07409181 | P2 | recruiting | Systemic Lupus Erythematosus | 405 | — |
All BI 3000202 trials (7)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07409181 | SLE | A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE) | P2 | recruiting | 405 | Boehringer Ingelheim | Apr 2026 |
| NCT07486102 | A Study to Test How BI 3000202 is Taken up in the Blood of People With and Without Liver Problems | P1 | recruiting | 44 | Boehringer Ingelheim | May 2026 | |
| NCT06878365 | A Study to Test How Well BI 3000202 is Tolerated by People With Type 1 Interferonopathies | P1 | active not recruiting | 16 | Boehringer Ingelheim | Jul 2025 | |
| NCT07273474 | A Study in Healthy Men and Women to Test How BI 3000202 is Taken up and Processed by the Body | P1 | completed | 12 | Boehringer Ingelheim | Dec 2025 | |
| NCT07215260 | A Study in Healthy People to Test Whether BI 3000202 Affects How 2 Other Medicines (Rosuvastatin and Digoxin) Are Taken up in the Body | P1 | completed | 14 | Boehringer Ingelheim | Nov 2025 | |
| NCT06327256 | A Study in Healthy People to Test How Well Different Doses of BI 3000202 Are Tolerated and How They Affect the Way the Body Handles Midazolam | P1 | completed | 40 | Boehringer Ingelheim | Apr 2024 | |
| NCT05945888 | A Study in Healthy Men to Test How Different Doses of BI 3000202 Are Tolerated and How Food Influences the Amount of BI 3000202 in the Blood | P1 | completed | 68 | Boehringer Ingelheim | Jul 2023 |
BI 3000202 clinical trials: frequently asked questions
- How many BI 3000202 clinical trials are there?
- 7 BI 3000202 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 2 are actively recruiting participants. 4 are marked completed.
- Are BI 3000202 clinical trials recruiting in 2026?
- Yes — 2 BI 3000202 trials are actively recruiting in 2026, with 1 U.S. site across 1 state. See the recruiting trials and the per-state site list further down this page.
- What conditions is BI 3000202 being studied for?
- BI 3000202 is being studied for Healthy, Hepatic Impairment, Systemic Lupus Erythematosus, Type 1 Interferonopathies. The trials are grouped by indication on this page.
- What phase is BI 3000202 in?
- BI 3000202 clinical trials span 1 Phase 2, 6 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors BI 3000202 clinical trials?
- The lead sponsor across the most BI 3000202 trials is Boehringer Ingelheim. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming BI 3000202as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: